Zacks Investment Research upgraded shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) from a hold rating to a buy rating in a research note issued to investors on Friday. They currently have $12.00 price objective on the biotechnology company’s stock.
According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Several other research firms have also commented on MCRB. FBR & Co reiterated an outperform rating and issued a $18.00 price objective on shares of Seres Therapeutics in a research note on Monday, March 20th. Canaccord Genuity set a $20.00 price objective on shares of Seres Therapeutics and gave the company a buy rating in a research note on Monday, June 12th. Cantor Fitzgerald reiterated an overweight rating on shares of Seres Therapeutics in a research note on Tuesday, March 21st. Finally, Cowen and Company reiterated a buy rating on shares of Seres Therapeutics in a research note on Friday, May 19th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $21.33.
Seres Therapeutics (NASDAQ:MCRB) traded up 6.20% during mid-day trading on Friday, hitting $12.17. The company had a trading volume of 138,798 shares. The company’s 50 day moving average price is $10.29 and its 200-day moving average price is $10.15. The firm’s market capitalization is $491.55 million. Seres Therapeutics has a 12-month low of $8.05 and a 12-month high of $35.98.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. Seres Therapeutics had a negative net margin of 441.10% and a negative return on equity of 68.86%. The business had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $3 million. During the same quarter last year, the firm earned ($0.50) EPS. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. On average, analysts forecast that Seres Therapeutics will post ($2.65) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2017/07/18/seres-therapeutics-inc-nasdaqmcrb-lifted-to-buy-at-zacks-investment-research.html.
A number of large investors have recently bought and sold shares of MCRB. Vanguard Group Inc. raised its stake in Seres Therapeutics by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock valued at $17,645,000 after buying an additional 103,456 shares during the period. Renaissance Technologies LLC raised its stake in shares of Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the biotechnology company’s stock valued at $3,963,000 after buying an additional 103,800 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares during the last quarter. State Street Corp raised its stake in shares of Seres Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 275,970 shares of the biotechnology company’s stock valued at $2,733,000 after buying an additional 16,671 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Seres Therapeutics by 5.8% in the first quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock valued at $1,874,000 after buying an additional 9,060 shares during the last quarter. Hedge funds and other institutional investors own 75.51% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
